Because most cancer patients die of metastatic disease, there is substantial interest in understanding--and pharmacologically thwarting--the molecular events that drive or facilitate metastasis. Early in the process within the primary tumor, cells attach to and migrate along collagen networks, which take them to blood vessels that carry them to distant organs they ultimately colonize. The Abramson Family Cancer Research Institute (AFCRI) lab of Celeste Simon, PhD, and postdoctoral fellow, T.S. Karin Eisinger-Mathason, PhD, report in Cancer Discovery about the potential of the collagen-modifying enzyme PLOD2 as a new therapeutic target for the treatment of metastatic undifferentiated pleomorphic sarcoma. Simon is the AFCRI Scientific Director, and Investigator with the Howard Hughes Medical Institute, and a professor of Cell and Developmental Biology. Their work was highlighted in Science magazine Editor's Choice column.